Genenta Science S.p.A.
Genenta Science S.p.A. (GNTA): 2 pipeline candidates · 2 upcoming catalysts · ~12 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.0 months
0% dilution
Lead: Phase 1/Phase 2
2 candidates
2 upcoming, next in ~2063d
N/A
A transparent, data-derived signal for Genenta Science S.p.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$44.1M
Cash
$5.5M
Quarterly Burn
$6.9M
Runway
12.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| cabozantinib | Phase 1/Phase 2 |
| temferon | Phase 1/Phase 2 |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$511K
| Holder | Shares | Value |
|---|---|---|
| eurizon capital sgr s.p.a. | 360,000 | $242K |
| alti global, inc. | 200,288 | $135K |
| smartharvest portfolios, llc | 134,447 | $90K |
| xtx topco ltd | 24,527 | $16K |
| morgan stanley | 15,420 | $10K |
| gamma investing llc | 14,288 | $10K |
| simplicity wealth,llc | 12,211 | $8K |
| farther finance advisors, llc | 3 | $2 |
Frequently asked questions
How many drug candidates are in Genenta Science S.p.A.'s pipeline?
Genenta Science S.p.A. (GNTA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Genenta Science S.p.A.'s lead drug candidate?
Genenta Science S.p.A.'s most advanced tracked candidate is cabozantinib (Phase 1/Phase 2) for Clear Cell RCC.
What is Genenta Science S.p.A.'s next catalyst?
Genenta Science S.p.A.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: COMETRIQ" — expected February 10, 2032.
What is Genenta Science S.p.A.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Genenta Science S.p.A. has approximately 12.0 months of cash runway.
What is Genenta Science S.p.A.'s market capitalization?
Genenta Science S.p.A.'s market capitalization is approximately $44.1M.
Get the full picture on Genenta Science S.p.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.